← Back to headlines
Capricor Therapeutics Nears Commercialization of Deramiocel with Strong Cash Balance and FDA Review
Capricor Therapeutics signals potential commercialization of its drug Deramiocel, backed by a $318 million cash balance and an ongoing FDA review milestone.
13 Mar, 00:02 — 13 Mar, 00:02
Sources
Showing 1 of 1 sources
